The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the ...
Comprehensive review synthesizes clinical learnings from BEXMAB and MATINS trials, detailing the potential of bexmarilimab in overcoming immune resistance in cancer TURKU, FI / ACCESS Newswire / ...
Doctors share what the findings may mean for the future of cancer treatment.
“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...
DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic TNBC Who Are Not Candidates ...
Phase 3 trial data show datopotamab deruxtecan reduces the risk of disease progression or death in patients with metastatic TNBC.
The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults ...
FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...
As immunotherapy becomes a cornerstone of cancer treatment, some of the top U.S. cancer centers and health systems are accelerating research efforts to identify the biological mechanisms behind ...
Checkpoint blockade immunotherapy may benefit patients with microsatellite stable colorectal cancer whose disease has not spread to the liver, according to research published Aug. 9 in JAMA Network ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results